Two hundred sixteen patients with a nonfollicular small cell lymphoma followed up in our department over a 5-year period have been reviewed t o define the clinical behavior and survival of patients with each histologic subtype. The respective frequencies of major subtypes were: small lymphocytic/lymphoplasmacytoid lymphoma (immunocytoma, SL/LPL), 28%; large cell-rich immunocytoma (LCRI), 7%; mantle cell lymphoma (MCL), 24%; mucosa-associated lymphoid tissue-lymphoma (MALT-L), 20%; other rare subtypes, 640; and nonclassified or nonreviewed, 1446. The SL/ LPL patients and the MALT-L patients had a relatively indolent disease, usually disseminated for SL/LPL and usually localized for MALT-L. Both subtypes have a long time t o treatment failure (lTF; median, 48 and 58 months, respectively) and long survival (median, 118 and 98 months, respectively). The LCRI patients or the MCL patients had more ag-OST OF THE nonfollicular small cell lymphomas (NFSCL) have an histologic pattern of infiltration that may be diffuse, although some of them show very distinctive infiltration patterns, such as true mantle zone, marginal zone, and interfollicular sinus, which may be very useful for their These lymphomas have been included in the low-grade category by pathologists, and, indeed, these patients do present a disease that is initially indolent. However, most of the patients experience progression of the lymphoma over the years and ultimately die from their disease. The pathologic features of these lymphomas were better described in the Kiel Classifi~ation~~~ than in the Working Formulation for Clinical U~a g e ,~.~ but none of these two classifications allows reliable characterization of these sub type^.^ NFSCL include small lymphocyticllymphoplasmacytoid lymphomas (SL/LPL8"o; small lymphocytic, immunocytoma, consistent with chronic lymphocytic leukemia [CLL], lymphoplasmacytoid); mantle cell lymphomas (MCL'1"4; centrocytic, intermediate lymphocytic); mucosaassociated lymphoid tissue-lymphoma (MALT-L)'5"7; monocytoid B-cell lymphoma'8-20; splenic lymphoma with circulating villous lymphocytes (SLVL)21*22; and other less well-Characterized lymphoma s~b t y p e s .~~, '~ The malignant small cells have a B-cell phenotype in more than 90% of the cases and are thought to originate respectively from the interfollicular zone (SLLPL), the mantle zone of the follicles (MCL), and the marginal or sinusal zones (MALT-L, monocytoid, and SLVL). If the morphologic description of these lymphomas is now well known and reproducible, patient clinical presentation and behavior, response to treatment, and prognostic factors have not yet been well characterized.
gressive clinical or biologic features and experienced shorter l T F (median, 26 and 14 months, respectively) and shorter survival (median, 55 and 52 months, respectively). None of these histologic subtypes was associated with a significant cure rate. MALT-L patients did relapse regardless of the initial localization or treatment and at a similar rate to the SL/ LPL patients. Factors associated with a worse outcome in nonfollicular small cell lymphoma patients are identical t o those described in other lymphoma subtypes: advanced clinical stage, poor performance status, high tumor bulk, and high iactic dehydrogenase or &microglobulin levels. For patients with disseminated disease, standard chemotherapy regimens did not allow a long lTF; therefore, new therapeutic strategies must be developed.
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centers, and a total of 216 (19.8%) patients were diagnosed as NFSCL. The available pathologic specimens were reviewed and analyzed by three of us (FB, PF, and PAB) without knowledge of the clinical outcome. All slide specimens obtained at diagnosis and from subsequent biopsies performed during relapse or progressive phases, whether they originated from nodal, bone marrow, or extranodal localizations, were reviewed by all possible histologic, cytologic, and immunologic methods to classify the lymphoma as accurately as possible. Immunologic characterization was realized on paraffin section in 85% of the cases, on frozen section in 54%, and on cell suspension in 47%. A total of 185 patients had an unequivocal diagnosis of NFSCL with a particular subtype and are presented in this analysis (see Table 1 ). The materials from 15 (6.9%) patients could not be reviewed, and those patients were excluded from this analysis as were the 16 (7.4%) patients for which a definitive diagnosis of the NFSCL subtype could not be made after revision. Patients with an SULPL and a lymphocytosis greater than 10 G/I were deemed to have a CLL and were not included in this analysis. The 13 patients with rare subtypes (monocytoid, SLVL, and others; see Table 1 ) were only considered for global analyses.
Patients were split into five subgroups according to histologic subtype: SLILPL, large cell-rich immunocytoma (LCRI), MCL, MALT-L, and other rare subtypes. SLJLPL was defined by a monotonous infiltration of small, round lymphocytes with a clumped chromatin and the presence of pseudofollicular proliferation centers with prolymphocytes and paraimmunoblasts; in addition, LPL was de- fined by a varying number of lymphoplasmacytoid cells with moderate to abundant basophilic cytoplasm, frequent nuclear Dutcher bodies, and inconstant Russel b~d i e s .~. *~ Among the lymphoplasmacytoid cell lymphomas, LCRI was defined by the presence of 20% to 50% immunoblasts and/or centroblasts (large noncleaved cells) and by an increased number of mito~es.~ MCL was defined by a diffuse, nodular, or mantle zone pattern of infiltration; lack of pseudofollicular proliferation centers; inconstant naked follicular centers; small to medium sized cells with usually irregular or indented, sometimes round, rarely cerebriform nuclei; variable, fine to moderately coarse, but rarely clumped, chromatin; and scant cytoplasm.' '.I4 MALT-L was defined by the presence of extranodal localization; the usual presence of reactive, nonneoplastic follicles and lymphoepithelial lesions; the tumoral infiltration around reactive follicles by small to medium sized cells with either irregular nuclei (centrocytic-like) or more regular nuclei and abundant clear cytoplasm (resembling monocytoid B-cell); and an inconstant, variable plasma cell differentiation.26 Monocytoid B-cell lymphoma was only considered in case of sinusal or interfollicular patterns of infiltration in patients with nodal disease. Other rare subtypes were classified according to original publications.*'
Treatments. Initial staging procedures included thorax and abdominal computerized tomography, bone marrow biopsy, and dosage of blood levels of lactic dehydrogenase (LDH) and P,-microglobulin. Patients were treated according to initial diagnosis, their stage, and presence or absence of a large tumor mass by various therapeutic modalities (see Table 2 ). Localized lymphoma patients were usually treated with involved field radiotherapy (if disease was confined to nodal areas) or with surgery (if disease was extranodal). Disseminated lymphoma patients were usually treated with chemotherapy, single agent (intermittent courses of chlorambucil 5 days a month) or multidrug regimens (CVP [cyclophosphamide, vincristine, and prednisone] or CHOP-like [CVP plus doxorubicin] regimens). Twenty recent SLLPL or MCL patients were included in a prospective phase I1 study of fludarabine as initial treatment. Twenty-two patients with an aggressive clinical feature at diagnosis were treated according to the LNH-84 regimen."
Statistics. Overall survival was defined as the time from diagnosis (first biopsy) to death or last follow-up. Time to treatment failure (TTF) was defined as survival from onset of treatment to progression of the lymphoma, to death from toxic event, or to last follow-up. Statistical analyses were made with the chi-square test or the logrank test." Tables 1 and 3 show the different patient groups according to lymphoma subtypes and clinical characteristics. Compared with the 61 SLLPL patients, the 52 MCL patients were older, usually had a disseminated disease with frequent extranodal localizations (particularly splenic or digestive localizations), commonly had a bulky tumor, and had increased LDH or P,-microglobulin levels. Both diseases were regularly disseminated with only 11% to 23% of the patients having localized stage disease. Of the MCL patients, 89% had stage IV disease, nearly all of them with bone marrow involvement, and 65% of these stage IV patients had two or more extranodal localizations. In 50% of MCL patients and in 41 % of SLLPL patients, circulating lymphoma cells were noticed. MCL patients with gastrointestinal disease tended to have multiple involved areas with more frequently colic localizations than did the other subtypes. Of these patients, 6 presented multiple lymphomatous polyposis. Then, the clinical figure of MCL patients compared with those of other NFSCL patients is more that of an aggressive lymphoma ( Table 3) . Only one patient with MCL and a pure mantle zone pattern of infiltration was seen; therefore, it is difficult to evaluate the better outcome that has been associated with this subtype.29 A total of 12 MCL patients had a partially nodular pattern of infiltration.
RESULTS
If SLLPL patients had a relatively indolent disease, they presented with more symptoms than did CLL patients because of the presence of peripheral or abdominal enlarged lymph nodes, extranodal localizations, and splenomegaly. Less than 25% of SLLPL patients had a poor performance status (PS), B symptoms, or a bulky tumor, and less than 30% of them had a high LDH level. Patients with LCRI, when compared with SLLPL patients, had a more aggressive disease, with half of them presenting poor PS, B symptoms, or extranodal localizations (Table 3) . These LCRI patients presented with commonly biologic abnormalities associated with disease aggressiveness, such as high LDH and &mi-croglobulin levels, anemia, or low serum albumin level (Table 3). MALT-L was diagnosed in 43 patients. Patients with MALT-L, when compared with SULPL or MCL patients, had an indolent disease that was localized in 79% of them. Of the MALT-L patients, 27 (63%) had gastrointestinal localizations that always included gastric involvement. Of these 27 patients, 3 also had liver involvement, 2 had enteric involvement, 1 had colic localization, and 1 had pancreatic localization. Of these gastrointestinal MALT-L patients, 10 patients had associated abdominal nodal involvement, usually in the mesenteric areas. The remaining 16 patients had a nongastrointestinal MALT-L: 5, orbital; 3, pulmonary; 3, parotid; 2, tonsillar; 2, thyroid; and 1 breast. Bone marrow was involved in 3 patients, spleen in 2, and pleura in 2, and only 1 patient had circulating lymphoma cells. Biologic abnormalities were less frequent in MALT-L patients than in other subtypes: 15% of the patients had an anemia; 17%, a low serum albumin level; 12%, an above normal LDH level; and 19%, a 2 3 mg/L &microglobulin level. Therefore, at least one fourth of these MALT-L patients did not have a true localized disease.
Because of the diversity of therapeutic approaches, the response to treatment and the duration of response or of survival can only be analyzed for some subgroups. Fludarabine results are too preliminary to be analyzed. Table 4 presents the response rate to treatments, median TTF, and median survival according to diagnosis. Response rates decreased from SULPL to MCL and LCRI patients with an associated decrease in median TTF and in median survival. Histologic progression was observed in 3 1 patients (Table  4) . MALT-L with large cells were simply considered as MALT-L26 and were not regarded as histologic progression. MCL usually relapsed with a small increase in the cell diameter and in the number of mitosis without true histologic conversion into a large cell lymphoma. This may explain the lower histologic progression rate we have observed in these MCL patients, despite the high failure rate and the 
mortality rate. However, MALT-L and MCL patients may present true histologic conversion (Table 4) , and this was associated, as in other lymphoma subtypes, with a shorter survival (data not shown).
Although our study is retrospective and treatment was allocated to patients according to the initial clinical features and the supposed aggressiveness of the disease at the time of diagnosis, it is interesting to consider the results of each treatment type to formulate ideas about what possible future therapy to propose for these patients. Patients with LCRI and MCL treated with local therapy had shorter TTF (26 and 22 months, respectively) than did SLLPL or MALT-L patients in the same situation (108 and 58 months, respectively). MALT-L patients treated with chemotherapy had TTF that was not different from MALT-L patients treated with local treatment (44 and 58 months, respectively). None of the treatments was associated with prolonged 'ITF or prolonged survival in LCRI and MCL patients. Fludarabine seemed to have a promising activity in SL/LPL patients (median TTF not reached).
Major clinical and biologic parameters associated with shorter TTF or shorter survival for the whole population of 216 NFSCL patients are presented in Table 5 . A poor outcome was associated with an age older than 60 years, poor PS, disseminated disease with 2 2 extranodal sites, bulky tumor, circulating lymphoma cells, above normal LDH level or z 3 mg/L &microglobulin level, and splenomegaly. If the presence of gastrointestinal localization was associated with longer TTF, there was no difference regarding survival. Because of the low number of patients in each subtype, only highly significant prognostic factors may be isolated. Above normal LDH level was associated with shorter survival for LCRI and MCL patients, and 2 3 mg/L &microglobulin level was associated with shorter survival for SL/LPL, LCRI, MCL, and MALT-L patients. The International Non-Hodgkin's Lymphoma (NHL) Prognostic Index was initially described for diffuse large cell lymphomas3' and is based on the number of adverse prognostic factors: disseminated stage, poor PS, and above normal LDH level. When applied to NFSCL patients, this index discriminated three subgroups of patients with a good prognosis (0 factor), an intermediate prognosis (1 or 2 factors) , and a poor prognosis (3 factors) ( P < as shown in Fig 3. The index proposed by the M.D. Anderson Cancer Center (Houston, TX)" and based on &microglobulin and LDH levels may also separate patients into subgroups with distinct survival ( P < (Fig 4) .
DISCUSSION
This large series of lymphoma patients collected during 5 years provides interesting indications concerning the respective number of different lymphoma subtypes in a referring center. Our recruitment confirms the relative increase of NHLs compared with Hodgkin's disease, 85% versus 15% compared to 55% versus 45% in the same city 15 years ago (data not shown). Diffuse large cell lymphoma is the largest subtype among NHLs followed by NFSCL and follicular lymphomas. Adult patients with lymphoblastic and small noncleaved (Burkitt's) lymphomas are relatively infrequent. The new figure that appears in this series is the increasing number of patients with the so-called nonfollicular small cell lymphoma. This subgroup is heterogeneous and comprises SWLPL, LCRI. MCL, MALT-L, and other rare subtypes as previously described. NFSCL lymphomas seem to have been recognized more frequently in recent years but this may be associated with an increasing interest for these subtypes and an increase of referring to our center. The four major subtypes of NFSCL clearly correspond to different categories, because they present distinctive clinical characteristics and outcome, and, thus, have to be considered as different categories by physicians who treat these patients. MALT-L patients usually present with extranodal localization, but the disease remains localized without any adverse prognostic factor such as bone marrow involvement or high LDH or P2-microglobulin levels. MALT-L is associated with a high response rate with local or chemotherapy treatment, with long l'TF, and with long survival. SLLPL is a more disseminated disease with multiple nodal sites and frequent involvement of bone marrow without high LDH or Pz-microglobulin levels. SLJLPL is also associated with long 'ITF and long survival. On the other hand, MCL and LCRI are the most aggressive diseases with a highly disseminated presentation, high levels of LDH and P*-microglobulin, short "TF, and short survival (Figs 1 and 2) . A summary of clinical features and of outcome frequently associated with the different subtypes is presented in Table 6 .
If SL lymphoma has the morphologic characteristics of CLL? LPL has been individualized because of the presence of a varying number of lymphoplasmacytoid cells with moderate to abundant basophilic cytoplasm. Both lymphomas have similar clinical manifestations, with extranodal involvement, large nodal masses and no massive blood involvement, and these are clearly distinct from the clinical expression of common CLL. However, no clinical difference seems to exist between small lymphocytic and lymphoplasmacytoid lymphomas. Their treatment may not be different from that of CLL. Indeed, we have observed a response in 7 of our 7 patients treated with fludarabine with only 1 progression (data not shown). This promising treatment in CLL may also be recommended for SL/LPL patient^.^^'^^ LCRI was not individualized in the Working Formulation (LCRI patients have probably been included in the A or F classes) but has been described in the original version of the Kiel Classification as polymorphic imm~nocytoma.~.~~ The name "immunocytoma with high content of blast cells" was recently proposed by Lennert (personal communication, April 1992) but has not yet been introduced in any published classification. This lymphoma differs from LPL in its morphologic aspect, its more aggressive initial clinical characteristics, and its worse outcome. It is diagnosed in patients with 20% to 50% immunoblastic or blastic large cells among lymphoplasmacytoid cells. A higher number of mitoses is habitually found in LCFU compared with that in SLLPL. LCRI may also be considered as an early transformation of SLLPL when diagnosed. It must be distinguished from the For personal use only. on March 30, 2017. by guest www.bloodjournal.org From diffuse large cell lymphomas (centroblastic or immunoblastic) with a high number of small reactive T cells by the plasmacytoid differentiation of the small B cells. Our data support the definition of the LCRI subtype as a distinct entity with a worse prognosis among small B-cell lymphomas.
In our experience, the gastrointestinal tract, and essentially the stomach, is the most frequently involved site of MALT-L. The diagnosis is not difficult if the biopsy specimen is sufficiently large, a case that is usual if a surgical biopsy has been performed. However, the diagnosis of MALT-L may be more difficult on small endoscopic biopsy specimens or in other extranodal localizations. MALT-L may sometimes be misdiagnosed as an SL/LPL, because of the plasmacytic differentiation, or as an MCL, because of the centrocytic-like cells. The expression of CD5 antigen on lymphoma cells may allow the diagnosis of MCL or SL/ LPL. The rare true follicular lymphoma developed in the gastrointestinal tract may be recognized by the expression of CD10 antigen. The diagnosis between MALT-L and monocytoid B-cell lymphoma may be quite difficult when examining a nodal biopsy specimen, because these two lymphomas are thought to originate from the same cell and have close morphologic characteristi~s.'~~'~ MCL may be misdiagnosed as an SL/LPL in the cases where prolymphocytic cells with round nuclei are more abundant than the classical centrocytic cells described by L e n n e~t .~ These difficulties may explain why we have found 16 patients with composite lymphoma imitating several of the described entities; we have described these lymphoma as "nonclassifiable" ( Table 1) . These cases may be borderline because of the absence of the typical characteristics of one subtype or because of the association in the same biopsy specimen of different cell populations, ie, MCL and SL/LPL or MCL and follicular. In these patients, the determination of immunologic phenotype may not be sufficient to determine the actual subtype of the lymphoma (ie, coexpression of CD5 and CDIO). However, the presence of a specific genomic rearrangement (translocation 11; 14 or translocation 14; 18)" or an overexpression of the bcl-l gene" may contribute to the diagnosis.
The Working Formulation identified a subcategory, E, for diffuse small cleaved-cell lymphoma. Many of the patients described in this study might have been included in this subcategory 10 years ago,37 particularly MCL patients, some LPL patients, and some MALT-L patients. This E subcategory is, in fact, a mixture of different categories, such as follicular lymphoma with a high percentage of diffuse areas that should be recognized by the cleaved nuclei and the follicular pattern of infiltration in small areas; SWLPL with large pseudoproliferation centers; MCL; MALT and monocytoid lymphomas; and some small T-cell lymphomas. As shown here, these morphologic subtypes correspond to different clinical features and outcomes. Therefore, this diffuse small cleaved-cell or E lymphoma subtype should disappear in the future classification of NHLs.'.~.'~ Despite the heterogeneity of NFSCL patients described in this analysis, adverse prognostic factors associated with a shorter TTF or a shorter survival are not different from prognostic factors identified for other lymphoma ~u b t y p e s .~~. '~.~~ As in all lymphoma subtypes, above normal LDH level and high &-microglobulin level are associated with a poor outcome as well as high tumor burden and poor PS. No specific prognostic indicators may be identified for these NFSCL as a whole category or for a particular subtype. Although our results need to be confirmed on larger patient series, the International NHL Prognostic Index" seems useful to describe the outcome of NFSCL patients and to stratify them for therapeutic studies.
